Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Somatic epidermal growth factor receptor (EGFR) mutations are present in around 50% of Asian patients and in 10–15% of Caucasian patients with metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The first-generation EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotini...

Description complète

Détails bibliographiques

Auteurs principaux:	Sami Morin-Ben Abdallah, Vera Hirsh
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2017-05-01
Collection:	Frontiers in Oncology
Sujets:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor afatinib gefitinib erlotinib
Accès en ligne:	http://journal.frontiersin.org/article/10.3389/fonc.2017.00097/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!